Overview

Medtronic plc is a global medical-technology company whose products are used to diagnose, monitor, manage, and treat a broad range of chronic and acute medical conditions. Its portfolio includes cardiac rhythm devices, structural-heart and vascular technologies, insulin pumps and diabetes-management systems, spinal implants and biologics, neurostimulation systems, surgical-navigation technologies, patient-monitoring equipment, respiratory-care products, and renal-care technologies. The company serves hospitals, physicians, health systems, and patients, with operations spanning more than 150 countries. The business began in Minneapolis in 1949 as a medical-equipment repair shop founded by Earl Bakken and Palmer Hermundslie. Its early repair work brought Bakken into contact with cardiac surgeon C. Walton Lillehei. Following a 1957 power outage during which a pacemaker-dependent child died, Bakken developed a battery-powered external pacemaker based on a transistorized metronome. This innovation helped establish Medtronic's long-term focus on portable, implantable, and electrically controlled therapies. The company subsequently developed implantable pacemakers and expanded into defibrillation, cardiac monitoring, neuromodulation, and other implantable technologies. Medtronic grew through internal research, international manufacturing, and acquisitions. Important additions included Vitatron in the cardiac-rhythm field, Physio-Control, Kyphon in spinal care, and MiniMed in diabetes management. The 2015 acquisition of Irish-based Covidien substantially broadened the company's minimally invasive therapies, surgical, monitoring, and respiratory portfolios and resulted in the company's legal and executive headquarters being established in Ireland, while Minneapolis remained its principal operational center. The transaction also made Medtronic a prominent example of a U.S. corporate tax inversion, generating sustained public and political scrutiny. Medtronic organizes its activities across major areas including cardiovascular, medical-surgical and acute-care monitoring, diabetes, restorative therapies, neuromodulation, and spinal and biologics. Its technologies are used in procedures and long-term treatment programs for heart rhythm disorders, heart failure, coronary and peripheral vascular disease, spinal disorders, chronic pain, movement disorders, diabetes, and other conditions. The company has also invested in remote monitoring, connected devices, surgical video analytics, navigation, and data-enabled care. Notable innovations associated with the brand include wearable and implantable pacemakers, implantable cardioverter-defibrillators, remote patient-monitoring systems, small-format pacemakers, spinal-cord stimulators, and the MiniMed 670G hybrid closed-loop insulin-delivery system. Medtronic has faced product-safety, regulatory, litigation, and reimbursement controversies, including recalls involving Sprint Fidelis defibrillator leads and the HeartWare ventricular-assist system, as well as a federal settlement concerning alleged Medicare fraud related to kyphoplasty reimbursement practices. These events have influenced its quality controls, product oversight, and public reputation. In the 2020s, Medtronic expanded through acquisitions and partnerships in electrophysiology, diabetes, spine, surgical data, and renal care. It announced plans with DaVita to create an independent kidney-care medical-device company; the renal-care business later became Mozarc Medical. In 2024, Medtronic abandoned a proposed separation of its patient-monitoring and respiratory-interventions activities, combined them into an Acute Care & Monitoring unit, and announced that it would discontinue its ventilator product line because of poor profitability. The company remains an active, diversified medical-device manufacturer with a strong emphasis on implantable therapies, minimally invasive procedures, chronic-disease management, and connected healthcare.

History

Medtronic was established in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a repair business for medical equipment. The company's formative period connected it with cardiac surgeon C. Walton Lillehei, whose work exposed the limitations of early pacemakers. During a 1957 power failure in Minnesota and Wisconsin, a pacemaker-dependent pediatric patient died. Bakken responded by adapting a transistorized metronome into a battery-powered external pacemaker. The compact device could be attached to the patient's body and removed without another operation, addressing the dependence of earlier systems on mains electricity. Medtronic continued to sell equipment made by other manufacturers while developing its own devices. It introduced increasingly portable pacemakers and moved toward implantable systems, producing an implantable pacemaker by 1960. The company built a headquarters in St. Anthony, Minnesota, in 1960 and later moved operations to Fridley. Cardiac-rhythm management remained its foundational business, eventually expanding from pacing into defibrillation, cardiac-resynchronization therapy, monitoring, and remote patient management. The company broadened geographically and technologically through the second half of the twentieth century. Its acquisition of Vitatron in 1986 added a European pacemaker business, while the 1998 purchase of Physio-Control expanded its emergency and patient-care portfolio. In 1997, Medtronic opened a Swiss production and training site for implantable pacemakers and related devices. The acquisition of MiniMed in 2001 created the foundation of the modern diabetes business and brought insulin pumps into the company's principal therapeutic portfolio. Kyphon, acquired in 2007, strengthened spinal-fracture and spine-implant activities. Medtronic's expansion accelerated through acquisitions and portfolio transactions in the 2010s. It acquired or added businesses in surgical instruments, dialysis-related equipment, cardiac support, spine surgery, nutrition analytics, diabetes technology, and vascular care. The largest strategic change came in 2015, when Medtronic acquired Covidien. Covidien brought substantial minimally invasive therapies, surgical, monitoring, and respiratory businesses and made Ireland the company's legal and executive base. The transaction was also criticized as a large U.S. tax inversion, making Medtronic a recurring subject of tax-policy debate. The company continued to build its technology portfolio through acquisitions of Bellco, HeartWare, Crospon, Mazor Robotics, Nutrino Health, Titan Spine, Stimgenics, Medicrea, Companion Medical, Avenu Medical, and Affera, among others. These transactions supported growth in renal care, ventricular support, spine robotics, nutrition data, spinal stimulation, diabetes-management software, reconstructive spine implants, and cardiac electrophysiology. Medtronic also developed partnerships around surgical video analytics, ambulatory surgery, coronary diagnostics, and kidney care. Its diabetes business became particularly visible after the FDA authorized the MiniMed 670G in 2016. Launched in 2017, the system was described as the first FDA-approved hybrid closed-loop insulin pump, using sensor data and an algorithm to adjust basal insulin delivery for people with type 1 diabetes. In cardiac care, the company continued miniaturization and remote monitoring, while in neuromodulation it developed systems for chronic pain, movement disorders, and other conditions. Medtronic has also experienced significant product-safety and compliance challenges. The 2007 Sprint Fidelis lead recall followed reports of excessive lead failures. In 2008, it paid $75 million to resolve allegations involving the classification and reimbursement of kyphoplasty procedures. In 2021, the HeartWare HVAD system was recalled and regulators warned against new implants because of risks involving neurological events and mortality. These matters illustrate the regulatory and clinical risks inherent in implantable and life-sustaining medical technologies. In 2022, Medtronic announced an intended separation of its patient-monitoring and respiratory-interventions activities, but in 2024 it reversed that plan. The businesses were combined into Acute Care & Monitoring, while the company announced that it would discontinue ventilators because the product line was not profitable. Renal Care Solutions was separated into Mozarc Medical through a transaction involving DaVita. Medtronic remains an active international medical-technology company with a portfolio covering cardiovascular care, diabetes, surgical technologies, restorative therapies, neuromodulation, monitoring, and chronic-disease management.

2024
Acute Care & Monitoring is formed
[1]Medtronicen.wikipedia.org
Medtronic abandons the planned separation of patient monitoring and respiratory interventions, combines them into a new unit, and announces a ventilator exit.
2023
Renal Care Solutions becomes Mozarc Medical
[1]Medtronicen.wikipedia.org
The renal-care business is separated into an independent kidney-care medical-device company formed with DaVita.
2021
HeartWare HVAD recall
[1]Medtronicen.wikipedia.org
Medtronic recalls the HVAD system amid safety concerns and regulatory warnings against new implants.
2020
Geoff Martha succeeds Omar Ishrak as CEO
[1]Medtronicen.wikipedia.org
Geoff Martha becomes chief executive after Omar Ishrak's retirement from the CEO role.
2018
Mazor Robotics is acquired
[1]Medtronicen.wikipedia.org
The acquisition adds robotic and image-guided technologies for spine surgery.
2016
MiniMed 670G receives FDA approval
[1]Medtronicen.wikipedia.org
The FDA approves the MiniMed 670G hybrid closed-loop insulin-delivery system.
2015
Covidien acquisition changes corporate structure
[1]Medtronicen.wikipedia.org
The Covidien transaction expands Medtronic's minimally invasive and monitoring businesses and moves its legal and executive headquarters to Ireland.
2007
Kyphon is acquired and Sprint Fidelis leads are recalled
[1]Medtronicen.wikipedia.org
Medtronic strengthens spine care through Kyphon while recalling Sprint Fidelis defibrillator leads over failure concerns.
2001
MiniMed becomes part of Medtronic
[1]Medtronicen.wikipedia.org
The MiniMed acquisition establishes the core of Medtronic's insulin-pump and diabetes-management business.
1998
Physio-Control is acquired
[1]Medtronicen.wikipedia.org
Medtronic expands into emergency-care and related medical equipment through the acquisition of Physio-Control.
1997
Swiss pacemaker and training facility opens
[1]Medtronicen.wikipedia.org
Medtronic opens a production and physician-training site in Tolochenaz, Switzerland.
1986
Vitatron is acquired
[1]Medtronicen.wikipedia.org
The acquisition adds a Dutch pacemaker manufacturer and strengthens Medtronic's European cardiac-rhythm operations.
1960
Implantable pacemaker work advances
[1]Medtronicen.wikipedia.org
Medtronic produces an implantable pacemaker and establishes a larger headquarters in St. Anthony, Minnesota.
1957
Battery-powered external pacemaker developed
[1]Medtronicen.wikipedia.org
After a power outage exposes the danger of mains-powered pacemakers, Earl Bakken develops a compact battery-powered external pacemaker.
1949
Medtronic is founded in Minneapolis
[1]Medtronicen.wikipedia.org
Earl Bakken and Palmer Hermundslie establish the company as a medical-equipment repair shop.

Products and positioning

A high-end, clinically focused medical-technology leader combining implantable therapies, minimally invasive devices, chronic-disease management, and connected-care platforms.

Cardiovascular devices
Cardiac rhythm management systems
Medtronic's foundational product family includes pacemakers, implantable cardioverter-defibrillators, cardiac-resynchronization devices, leads, programmers, and remote-monitoring systems. These technologies are intended to detect or treat abnormal rhythms and support patients with selected heart-failure conditions. The portfolio grew from the company's early battery-powered and implantable pacemaker work.
Diabetes technology · 2001
MiniMed insulin-pump systems
MiniMed systems deliver programmed or algorithm-assisted insulin for people who require intensive diabetes management. The product family includes pumps, infusion sets, glucose sensors, software, and patient-management tools. Medtronic's diabetes business originated with MiniMed, which the company acquired in 2001.
Diabetes technology · 2017
MiniMed 670G
The MiniMed 670G is a hybrid closed-loop insulin-delivery system that uses continuous glucose information and an automated algorithm to adjust basal insulin delivery. FDA approval in 2016 and market introduction in 2017 made it a prominent milestone in automated insulin therapy.
Diabetes monitoring
Guardian continuous-glucose-monitoring technologies
Guardian sensors provide glucose readings that can be used with compatible Medtronic insulin pumps and management software. In systems such as the MiniMed 670G, sensor data supports automated basal-insulin adjustments and alerts intended to help users manage glucose levels.
Surgical navigation
StealthStation
StealthStation is a computer-assisted surgical-navigation platform used to help clinicians plan and navigate selected cranial, spinal, and neurological procedures. It integrates imaging, software, and surgical instruments to provide intraoperative guidance, particularly in minimally invasive or anatomically complex operations.
Surgical imaging
O-arm Imaging System
The O-arm is an intraoperative imaging platform associated with Medtronic's navigation and spine-surgery activities. It provides three-dimensional fluoroscopic imaging during procedures and can be integrated with navigation systems to support placement of implants and instruments.
Neuromodulation
Spinal-cord stimulation systems
Medtronic's spinal-cord stimulation systems deliver electrical stimulation intended to manage certain forms of chronic pain. The neuromodulation portfolio also includes technologies for movement disorders and implantable drug delivery, extending the company's original expertise in therapeutic electrical stimulation beyond cardiac care.
Heart-failure device
HeartWare HVAD
The HeartWare HVAD was an implantable ventricular-assist system designed to support circulation in selected patients with advanced heart failure. Medtronic recalled the system in 2021 and regulators advised against new implants because of safety concerns involving neurological adverse events and mortality.
Patient monitoring
Patient-monitoring and acute-care technologies
The Acute Care & Monitoring portfolio includes patient monitors, pulse-oximetry, capnography, bispectral-index sensors, remote-monitoring software, and connectivity tools. It incorporates technologies associated with businesses such as Nellcor, Oridion Medical, Aspect Medical Systems, Somanetics, and others acquired through Medtronic and Covidien.

Controversies

2021
HeartWare HVAD safety action
Medtronic recalled the HeartWare ventricular-assist system, and the FDA warned physicians to stop new implants because of increased risks of neurological adverse events and mortality associated with the internal pump.
Source
2021
Medtronic recalls Valiant thoracic stent graft batches in Brazil over label errors
Medtronic voluntarily recalled specified batches of its Valiant Thoracic Stent Graft with the Captivia Delivery System in Brazil after Portuguese-language product labels were found to contain errors in the product name and registration number. The report says the issue did not affect product performance, no complaints or related patient injuries had been reported, and no follow-up corrective action was needed because the affected products were limited to Brazil.
Source
2021
Medtronic recalls Pipeline Flex embolization devices
Medtronic recalled Pipeline Flex Embolization Devices after identifying a risk that delivery-system wires or tubes could fracture during device placement, retrieval, or movement. The article reports 59 malfunctions, 10 serious injuries, and two deaths related to the recall; the FDA identified it as a Class I recall.
Source
2020
FDA recalls certain MiniMed 600 series insulin pumps
The FDA issued a Class I recall covering more than 322,000 Medtronic MiniMed 600 series insulin pumps because a defective retainer ring may cause insulin over- or under-delivery. The article reports more than 26,000 complaints, 2,175 injuries and one death related to the pumps.
Source
2015
Tax-inversion controversy following Covidien transaction
The company's relocation of its legal and executive headquarters to Ireland after acquiring Covidien was criticized as a large U.S. corporate tax inversion. The transaction became a prominent example in public and policy debates about multinational tax structures.
Source
2008
Kyphoplasty reimbursement settlement
Medtronic Spine agreed to pay $75 million to settle a qui tam action alleging that healthcare providers were encouraged to classify kyphoplasty as inpatient treatment to obtain higher Medicare reimbursement. The settlement resolved the allegations without the supplied material establishing a broader admission of wrongdoing.
Source
2007
Sprint Fidelis lead recall
Medtronic recalled Sprint Fidelis defibrillator leads after failures were reported at an unacceptable rate. A failed lead could cause an inappropriate shock or prevent therapy when it was needed, creating serious clinical risk and litigation exposure.
Source

Marketing campaigns

MiniMed diabetes education and therapy-management programs
United States · International
Medtronic's diabetes business has supported insulin-pump adoption through patient education, clinician training, therapy-management services, and connected diabetes tools associated with its MiniMed portfolio.
Outcome. Supported the expansion of insulin-pump and sensor-based diabetes management; specific campaign metrics are not available in the supplied sources.
Source

Brand decisions

2022
Plan to separate Patient Monitoring and Respiratory InterventionsStrategy
Background
Medtronic evaluated a portfolio separation to focus the remaining businesses and improve strategic flexibility.
Action taken
The company announced an intention to spin off or sell the combined patient-monitoring and respiratory-interventions activities.
Aftermath
In 2024, Medtronic reversed the separation plan, created Acute Care & Monitoring, and chose to discontinue its ventilator product line.
Source
2022
Create an independent kidney-care medical-device company with DaVitaM&A
Background
Medtronic sought a dedicated structure for its renal-care products and technologies.
Action taken
Medtronic and DaVita announced plans to combine relevant activities in a new independent kidney-care company.
Aftermath
The renal-care business was subsequently separated into Mozarc Medical.
Source
2016
Launch the MiniMed 670G hybrid closed-loop systemProduct launch
Background
Insulin-pump users needed more automated support for basal insulin management and glucose control.
Action taken
Medtronic developed and introduced a pump-and-sensor system using SmartGuard automation and Guardian Sensor 3 data.
Aftermath
The system became a landmark FDA-approved automated insulin-delivery product and increased the visibility of Medtronic's diabetes technology.
Source
2015
Acquire Covidien and rebase the corporate headquarters in IrelandM&A
Background
Medtronic sought to expand beyond cardiac and implantable therapies into minimally invasive surgery, monitoring, and respiratory care.
Action taken
It completed the acquisition of Irish-based Covidien and made Ireland the legal and executive headquarters while retaining Minneapolis as the principal operational center.
Aftermath
The combination substantially broadened the portfolio and made the company a major subject of corporate-tax-inversion debate.
Source

Recent events

2024
Medtronic announces Acute Care & Monitoring structure and ventilator exit[1]Medtronicen.wikipedia.org
Product generation
Medtronic reversed plans to spin off or sell its patient-monitoring and respiratory-interventions businesses, combined them into a new Acute Care & Monitoring unit, and announced discontinuation of its ventilator product line.
2024
Medtronic changes plan for patient monitoring and respiratory businesses[1]Medtronicen.wikipedia.org
Leadership change
Medtronic reversed its previously announced separation plan, created an Acute Care & Monitoring unit, and discontinued its ventilator product line because the business was not profitable.
2022
Medtronic and DaVita plan independent kidney-care company[1]Medtronicen.wikipedia.org
M&A
Medtronic and DaVita announced plans to combine renal-care activities in a new independent medical-device company, later known as Mozarc Medical.
2018
Medtronic acquires Mazor Robotics[1]Medtronicen.wikipedia.org
M&A
The approximately $1.64 billion acquisition strengthened Medtronic's robotic and image-guided spine-surgery capabilities.
2016
Medtronic acquires HeartWare International[1]Medtronicen.wikipedia.org
M&A
Medtronic announced a transaction valued at approximately $1.1 billion to add HeartWare's ventricular-assist technologies.
2016
FDA approves MiniMed 670G hybrid closed-loop system[1]Medtronicen.wikipedia.org
Product launch · Regulation
The FDA approved Medtronic's MiniMed 670G, an insulin pump system capable of automatically adjusting basal insulin delivery using continuous glucose-monitoring data.
2015
Medtronic completes acquisition of Covidien and establishes Irish headquarters[1]Medtronicen.wikipedia.org
M&A
The acquisition significantly expanded Medtronic's surgical, monitoring, respiratory, and minimally invasive-therapy businesses and shifted the company's legal and executive headquarters to Ireland.
2015
Medtronic completes Covidien acquisition and redomiciles to Ireland[1]Medtronicen.wikipedia.org
M&A
The completed transaction materially expanded Medtronic's surgical, minimally invasive, monitoring, and respiratory businesses and established Ireland as its legal and executive base.
2014
Medtronic announces acquisition of Covidien[1]Medtronicen.wikipedia.org
M&A
Medtronic announced an agreement to acquire Covidien, creating the corporate structure that later placed its legal and executive headquarters in Ireland.